Clinical trialNCT02867800CompletedPhase 1Interventional

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

SponsorMonica BhatiaEnrollment24Graft Versus Host DiseaseSickle Cell Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To assess the tolerability of the costimulation blocking agent abatacept (CTLA4-Ig) when added to the standard graft versus host disease (GVHD) prophylaxis regimen of a calcineurin inhibitor and methotrexate in patients receiving early alemtuzumab followed by fludarabine, thiotepa, melphalan, and alemtuzumab for conditioning.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Monica Bhatia, MD
Columbia University
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S National Medical Center
Washington D.C., District of Columbia, United States
Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
Ann & Robert H. Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
Floating Hospital for Children at Tufts Medical Center
Boston, Massachusetts, United States
Columbia University Irving Medical Center
New York, New York, United States
North Carolina Cancer Hospital
Chapel Hill, North Carolina, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abatacept →Acetaminophen →Alemtuzumab →Cyclosporine →Diphenhydramine →Fludarabine →Melphalan →Meperidine →Methotrexate →Methylprednisolone →Mycophenolate mofetil →Sirolimus →Tacrolimus →ThiotepaLymphocyte immune globulin, anti-thymocyte globulin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2016
Primary completion: 30 Dec 2021
Completion: 30 Dec 2023
Last update posted: 13 Jun 2024
Registered enrollment: 24
Registry id: NCT02867800

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.